Nature Communications

Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial

2026-07-27

Full text

DOI https://doi.org/10.1038/s41467-026-75660-y